FLX-787-ODT ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	2

2. 筋萎縮性側索硬化症

---

臨床試験数 : 624 /  薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03334786 (ClinicalTrials.gov)	April 5, 2018	26/10/2017	Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS	An Open Label Study to Evaluate the Safety and Efficacy of FLX-787-ODT for Treatment of Fasciculations in the Tongue and One Appendicular Muscle in Adult Subjects With Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis;Fasciculation	Drug: FLX-787-ODT	Flex Pharma, Inc.	NULL	Terminated	18 Years	N/A	All	3	Phase 1/Phase 2	United States
2	NCT03338114 (ClinicalTrials.gov)	November 2017	6/11/2017	Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS	An Open Label Study to Evaluate the Safety and Efficacy of FLX-787-ODT for Treatment of Fasciculations in the Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis;Fasciculation	Drug: FLX-787-ODT (orally disintigrating tablet)	Flex Pharma, Inc.	NULL	Withdrawn	18 Years	N/A	All	0	Phase 1/Phase 2	United States